Will Icahn’s Double Biotech Win Augur M&A Action?


Published On: June 10th, 2009

IcahnBiogen Idec conceded two board seats yesterday to candidates backed by Carl Icahn and opposed by the company’s management. That came just over a week after a group of Amylin shareholders, led by Icahn and Eastbourne Capital Management, had candidates elected to two seats on Amylin’s board.

In typical fashion, Icahn has pushed for Biogen to consider a break-up or sale to a larger pharmaceutical company, this morning’s WSJ notes. And, as we noted last week, Amylin’s leaders have said Icahn wanted to arrange a sale of that company to Eli Lilly (though Icahn said they distorted his views).

Both Amylin and Biogen meet a few basic criteria that tend to make companies appealing takeover targets: They’re standalone biotech shops with products on the market. Amylin’s share price has fallen sharply over the past year, amid safety worries for its diabetes drug Byetta.

And Icahn’s track record is pretty solid; he’s played a key role in pushing for some big biotech deals in recent years, including AstraZeneca’s purchase of MedImmune and ImClone’s sale to Lilly.


Originally posted here: 
Will Icahn’s Double Biotech Win Augur M&A Action?

STOP PANIC ATTACKS - A Natural Technique To Stop Panic Attacks and Anxiety Fast!

Stop Panic Attacks
The technique I teach has been developed by me Joe Barry, a former sufferer of all too frequent panic attacks and GAD. I developed a completely natural approach to eliminating 100% of general anxiety and panic attacks. This may seem very hard to believe for someone who may have had this condition for some time but believe me the new information is now available to be free from anxiety. I will reveal the whole technique to you.

try-now

YouTube Video



Loading...


Did You Know Did you know:


Female breast cancer: Incidence rose between 1980 and 2001, then began to fall through 2005.

Related Posts

Leave a comment
Comments are closed.
« Health Reform: Kennedy Releases Bill, House Dems Get Rolling Hazy Data Complicate Drunk-Driver Measures »